Evidence map›Paper›PMID 42602965›Full record

ArticleiScience2026

Immunotherapy Efficacy in SMARC-Altered Cancers: A pan-cancer analysis of clinical outcomes in response to immune checkpoint inhibition.

Gregory P Botta, Wesleigh Edwards, Daisuke Nishizaki, Diana C Hargreaves, Shumei Kato, Razelle Kurzrock

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Gregory P BottaCenter for Personalized Cancer Therapy, Department of Medicine, University of California, San Diego, San Diego, CA, USA.
Wesleigh EdwardsDivision of Hematology/Oncology, Department of Medicine, Scripps Cancer Center, San Diego, CA, USA.
Daisuke NishizakiCenter for Personalized Cancer Therapy, Department of Medicine, University of California, San Diego, San Diego, CA, USA.
Diana C HargreavesSalk Institute for Biological Studies, La Jolla, CA 92037, USA.
Shumei KatoCenter for Personalized Cancer Therapy, Department of Medicine, University of California, San Diego, San Diego, CA, USA.
Razelle KurzrockDivision of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.

Funding

SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1M
VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DIANE M SIMEONE · 1985 to 2026
$124.9M
Institutional Career Development CoreKL2TR002552 · NCATS · SCRIPPS RESEARCH INSTITUTE, THE · PI NICHOLSON, LAURA · 2018 to 2022
$5.2M
Medical College of Wisconsin Lead Academic Participating Site RenewalUG1CA233198 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI William H Bradley, Elizabeth M Gore · 2019 to 2026
$5.0M
NCATS NIH HHS KL2 TR002552NCI NIH HHS L30 CA231689NCI NIH HHS P30 CA023100NCI NIH HHS U10 CA180888NCI NIH HHS UG1 CA233198
6 · The paper itself

Abstract

The switch/sucrose non-fermentable (SWI/SNF) chromatin remodeling complex and its SMARC subunits regulate gene expression. Altered SMARC is rare yet may enhance immunotherapy response. In this retrospective analysis of metastatic SMARC-altered solid tumors in the University of California San Diego (UCSD) medical record (6,831 patients), 53 patients with diverse SMARC-altered malignancies were evaluable. Outcomes were compared between patients receiving immune checkpoint inhibitors (ICIs;

Indexed as

immunotherapypan-cancerSMARC

Identifiers

PMID42602965
PMCPMC13475688

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.